Next Article in Journal
Paracoccidioides HSP90 Can Be Found in the Cell Surface and Is a Target for Antibodies with Therapeutic Potential
Next Article in Special Issue
Isavuconazole—Animal Data and Clinical Data
Previous Article in Journal
The High Osmolarity Glycerol (HOG) Pathway Functions in Osmosensing, Trap Morphogenesis and Conidiation of the Nematode-Trapping Fungus Arthrobotrys oligospora
Previous Article in Special Issue
Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species
Open AccessReview

Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data

by 1,2,* and 1,2
1
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA
2
Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA
*
Author to whom correspondence should be addressed.
J. Fungi 2020, 6(4), 192; https://doi.org/10.3390/jof6040192
Received: 2 September 2020 / Revised: 25 September 2020 / Accepted: 26 September 2020 / Published: 28 September 2020
(This article belongs to the Special Issue Antifungal Agents Recently Approved or Under Development)
Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique chemical stability conferring prolonged pharmacokinetics, as well as an administration advantage in the clinical setting compared to other drugs in the same class. Rezafungin displays potent in vitro activity against a wide spectrum of fungal pathogens, which is reflected in robust in vivo efficacy and/or pharmacodynamic studies using various animal models as well as in promising clinical trials data. This review describes in vivo characterization of rezafungin using animal models, current status of clinical development and key findings from these studies. View Full-Text
Keywords: rezafungin; invasive fungal infections; echinocandin; Candida; Aspergillus; Pneumocystis; pharmacokinetics/pharmacodynamics; efficacy; clinical trial rezafungin; invasive fungal infections; echinocandin; Candida; Aspergillus; Pneumocystis; pharmacokinetics/pharmacodynamics; efficacy; clinical trial
Show Figures

Figure 1

MDPI and ACS Style

Zhao, Y.; Perlin, D.S. Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data. J. Fungi 2020, 6, 192.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop